• Fumagillin: From MetAP-2 Biology to Translation

  2026-09-02

  Fumagillin is more than an antiangiogenic research reagent: it is a mechanistically defined methionine aminopeptidase-2 inhibitor that can connect endothelial biology, tumor-induced angiogenesis inhibition, and exploratory antiparasitic research. The strongest translational lesson is not simply whether the compound works, but how target biology, formulation, exposure, and host context determine whether in vitro activity becomes a useful model or a viable intervention.

• Losartan Workflows for Hypertension Research

  2026-09-02

  Build more informative hypertension and vascular assays with Losartan, a selective angiotensin II receptor antagonist that enables receptor-level interrogation of AT1 signaling. This guide connects vascular smooth muscle experiments with emerging podocyte-protection research while emphasizing practical dosing, controls, and troubleshooting.

• Okadaic acid: PP1/PP2A Inhibition Guide

  2026-09-01

  Okadaic acid (A4540) provides nanomolar inhibition of PP2A and PP1 for testing phosphorylation-dependent signaling and apoptosis-related endpoints. It is suited to controlled biochemical and cell-based experiments, but not to broad phosphatase inhibition, therapeutic use, or mechanistic conclusions based on apoptosis alone.

• Dexamethasone (DHAP): Time-Resolved Assay Design

  2026-09-01

  Dexamethasone is a glucocorticoid anti-inflammatory reagent whose biological effects depend strongly on exposure timing, cell state, and endpoint selection. This guide presents a time-resolved framework for studying NF-κB regulation, neuroinflammation, stem cell differentiation, autophagy, and RhoB biology with clearer causal interpretation.

• Angiotensin (1-7): Mechanism and Research Use

  2026-08-31

  Angiotensin (1-7), also known as Asp-Arg-Val-Tyr-Ile-His-Pro, is an endogenous heptapeptide that signals mainly through Mas and counter-regulates selected angiotensin II responses. The A1041 research reagent combines a defined peptide sequence with reported purity above 99.7%, water and DMSO solubility specifications, and preclinical model benchmarks.

• Periodontopathogens Redirect Angiotensin I to Ang-(1-7)

  2026-08-31

  The reference study shows that Porphyromonas gingivalis and Tannerella forsythia can reshape local renin–angiotensin system chemistry through surface-associated PepO metalloproteases that hydrolyze angiotensin I toward Angiotensin (1-7). Structural, biochemical, cellular, and infection-model data connect bacterial protease specificity with a potentially important mechanism linking periodontitis to host peptide signaling.

• Captopril Workflows for ACE Inhibition Research

  2026-08-30

  Use Captopril to connect quantitative ACE inhibition with hypertension research, bradykinin-sensitive gut motility assays, and exploratory cancer studies. This workflow emphasizes assay controls, concentration logic, solution stability, and the critical distinction between upstream ACE blockade and direct B2-receptor pharmacology.

• NF 449: Selective P2X1 Platelet Research Tool

  2026-08-29

  NF 449 combines exceptionally potent P2X1 antagonism with a mechanistically important Gαs-selective profile, making it useful for separating ATP-driven platelet signaling from broader purinergic effects. This guide outlines practical platelet workflows, assay controls, comparative applications, and troubleshooting strategies for reproducible antithrombotic agent research.

• Go 6983: PKC Signaling Workflow Guide

  2026-08-28

  Go 6983 is a practical pan-PKC inhibitor for resolving isoform-sensitive signaling, phorbol ester responses, and pathway-linked phenotypes in cancer progression studies. This guide combines dose-controlled PKC workflows with metabolism-aware assay design inspired by recent human blastoid research.

• BFH772 (VEGFR2 inhibitor): Use Guide

  2026-08-28

  BFH772 is a selective VEGFR2 kinase inhibitor for controlled studies of VEGFR2 signaling, endothelial responses, and tumor angiogenesis. It is best suited to organic-solvent-based workflows and should not be used where water solubility, broad kinase inhibition, or direct clinical efficacy evidence is required.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-27

  Oliveira et al. report that naturally occurring angiotensin fragments can increase the binding of SARS-CoV-2 spike protein to host-cell receptors, with the strongest activity observed for shorter, N-terminally truncated peptides. The study identifies peptide structure, especially modifications around tyrosine, as a potential determinant of spike–receptor interactions while also highlighting the need for cellular and in vivo validation.

• S63845 MCL1 Inhibitor: Apoptosis Workflow

  2026-08-27

  S63845 provides a selective way to test whether cancer cells depend on MCL1-mediated restraint of mitochondrial apoptosis. This workflow combines dose-response profiling with BAX/BAK, cytochrome c, caspase, PARP, and LACTB-aware readouts to distinguish pathway engagement from nonspecific toxicity.

• Captopril ACE Inhibitor: Workflows & Troubleshooting

  2026-08-26

  Captopril supports reproducible ACE inhibition in hypertension research while offering a practical probe for apoptosis induction in cancer cells and peptide-mediated gastrointestinal assays. This guide connects concentration planning, Angiotensin I-versus-II controls, and bradykinin B2 receptor experiments without overstating what the reference study directly demonstrated.

• BAPTA-AM: Calcium Chelation Workflows

  2026-08-26

  BAPTA-AM provides a practical way to test whether intracellular Ca²⁺ is a driver rather than a bystander in neuronal injury, apoptosis, and channel physiology. This guide combines concentration-controlled loading, calcium imaging, pathway-level validation, and troubleshooting for more interpretable experiments.

• Berbamine hydrochloride: NF-κB Assay Workflows

  2026-08-25

  Berbamine hydrochloride supports phenotype-to-mechanism workflows that connect viability, STAT3, calcium homeostasis, NF-κB signaling, and ferroptosis-related readouts. This guide shows how to use it as a carefully controlled perturbation tool in leukemia and hepatocellular carcinoma models without overstating pathway selectivity.

7730 records 1/516 page Next 12345 下5页 Last page